脱毛症治療薬の世界市場:タイプ別(円形脱毛症、男性型脱毛症)、エンドユーズ別、流通チャネル別、性別、地域別、

Grand View Researchが発行した調査報告書(GV905007)
◆英語タイトル:Alopecia Market Size, Share & Trends Analysis Report By Disease Type (Alopecia Areata, Androgenetic Alopecia), By End Use, By Sales Channel, By Gender, By Region, And Segment Forecasts, 2019 - 2025
◆商品コード:GV905007
◆発行会社(リサーチ会社):Grand View Research
◆発行日:2019年4月2日◆ページ数:86
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:Pharmaceuticals
◆販売価格オプション(消費税別)
Single UserUSD4,950 ⇒換算¥732,600見積依頼/購入/質問フォーム
Multi UserUSD5,950 ⇒換算¥880,600見積依頼/購入/質問フォーム
Global/corporate LicenseUSD7,950 ⇒換算¥1,176,600見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGrand View Research社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。Grand View Research社の概要及び新刊レポートはこちらでご確認いただけます。

本調査レポートでは、脱毛症治療薬の世界市場について調査・分析し、脱毛症治療薬の世界市場動向、脱毛症治療薬の世界市場規模、市場予測、セグメント別脱毛症治療薬市場分析、主要地域別市場規模、競争状況、関連企業情報などを含め、以下の構成でお届け致します。
【レポートの概要】

The global alopecia market size is anticipated to reach USD 12.37 billion by 2025, according to a report published by Grand View Research, Inc. It is expected to expand at a CAGR of 5.5% during the forecast period. Technological advancements, growing disease prevalence, and environmental pollution, and increase in per-capita healthcare expenditures across the globe are anticipated to propel the growth.
Factors such as new product launches and technological advancements are also impacting the market dynamics. For instance, Hairmax Laser comb, Follinex Massager Comb, Lifemax Infrared Hair Brush, and hair growth renewing lasers are some of the products built on advanced technology. Also, the launch of new drugs is improving the treatment success rate and clinical outcomes.

Based on condition, the market is classified into alopecia areata, androgenetic alopecia, and others. Androgenetic alopecia segment led the market in 2018 with revenue of USD 7,242.7 million and is anticipated to grow at a lucrative CAGR over the forecast period. Factors responsible for high revenue of this segment include availability of various treatments such as topical treatments and oral treatments involving the use of minoxidil and finasteride and surgical treatments like hair transplantation and replacement. On the other hand, alopecia areata is anticipated to expand at the fastest CAGR of 6.3% over the forecast period.

On the basis of end use, the alopecia market is segmented into homecare settings and dermatology clinics. Dermatology clinics led the market in 2018 with a revenue of USD 4,696.4 million, due to the presence of a large number of dermatology clinics with new technologies and high adoption of prescription hair care products. Homecare settings segment is anticipated to register the fastest CAGR of 6.0% during the forecast period. Increasing availability of many new OTC medications and products along with increasing preference for convenience and ease of use are some of the factors responsible for this growth.

North America led the market in 2018 and is anticipated to expand at a lucrative rate over the forecast period. Factors attributed to this high revenue are high prevalence of autoimmune disorders such as Polycystic Ovary Syndrome (PCOS) and cancer. Moreover, presence of advanced healthcare infrastructure, high disposable income, and novel therapeutic options are anticipated to further fuel the growth. Asia Pacific is anticipated to grow at the fastest rate over the forecast period owing to increasing awareness regarding available treatment options for alopecia and increasing per capital healthcare expenditure in emerging countries such as China and India.

Some of the key companies operating in the alopecia market are Cipla Inc.; Sun Pharmaceutical Industries Ltd.; Johnson and Johnson AG; Merck & Co., Inc.; and Lexington International LLC, Cirrus Hair Centers, Vita-Cos-Med Klett-Loch GmbH; Transitions Hair Pty Ltd., Follica, Inc. and Capillus.

Further key findings from the report suggest:

• Androgenetic alopecia segment led the market in 2018 with revenue of USD 7,242.7 million, owing to increasing prevalence of androgenetic alopecia and growing awareness regarding the availability of treatments

• Homecare settings is expected to witness the fastest CAGR of 6.0% over the forecast period owing to increasing preference for convenience and ease of use along with increasing availability of OTC medication

• Asia Pacific is expected to witness the fastest CAGR owing to the high population base, increasing availability of treatment options, and growing per capita healthcare expenditure

• Some of the key players in the alopecia market are Cipla Inc.; Sun Pharmaceutical Industries Ltd.; Johnson and Johnson AG; Merck & Co., Inc.; and Lexington International LLC, Cirrus Hair Centers, Vita-Cos-Med Klett-Loch GmbH; Transitions Hair Pty Ltd., Follica, Inc. and Capillus.

【レポートの目次】

Table of Contents

Chapter 1 Methodology and Scope
1.1 Market Segmentation & Scope
1.2 Market Definition
1.3 Information Procurement
1.3.1 Purchased Database
1.3.2 GVR’s Internal Database
1.3.3 Secondary Sources & Third Party perspectives
1.3.4 Primary Research
1.4 Information Analysis
1.4.1 Data Analysis Models
1.5 Market Formulation & Data Visualization
1.6 Data Validation & Publishing
Chapter 2 Executive Summary
2.1 Alopecia Market Outlook, By Revenue (USD Million)
2.2 Alopecia Segment Outlook, By Revenue (USD Million)
2.3 Competititve Insights
Chapter 3 Alopecia Market Variables, Trends and Scope
3.1 Penetration & Growth Prospect Mapping
3.2 Product Pipeline Analysis, by Stage
3.3 Industry Value Chain Analysis
3.3.1 User Perspective Analysis
3.3.1.1 Consumer behaviour analysis
3.3.1.2 Market influencer analysis
3.3.2 Cost structure analysis
3.4 Market Dynamics
3.4.1 Market driver analysis
3.4.1.1 Increasing prevalance of alopecia
3.4.1.2 Increasing prevalence of healthcare expensitures
3.4.1.3 Increasing prevalence of chronic diseases
3.4.1.3.1 PCOS
3.4.1.3.2 Cancer
3.4.1.3.3 Rheumatoid Arthritis
3.4.1.4 Technological advancements in alopecia treatment
3.4.2 Market restraint analysis
3.4.2.1 Lack of reimbursement policies for alopecia treatment
3.4.3 Industry challenges
3.5 Alopecia Market Analysis Tools
3.5.1 Industry analysis – Porter’s
3.5.1.1 Supplier power
3.5.1.2 Buyer power
3.5.1.3 Substitution threat
3.5.1.4 New entrants threat
3.5.1.5 Competitive rivalry
3.5.2 PESTEL Analysis
3.5.2.1 Political landscape
3.5.2.2 Economic landscape
3.5.2.3 Social landscape
3.5.2.4 Technology landscape
3.5.3 Major deals and strategic alliances analysis
3.5.4 Market entry strategies
Chapter 4 Alopecia Market – Competitive Analysis
4.1 Recent Developments & Impact Analysis, by Key Market Participants
4.2 Company/Competition Categorization
4.3 Public Companies
4.3.1 Company Market Position Analysis
4.3.2 Company Market Share/Ranking, by Region
4.4 Private Companies
4.4.1 List of Key Emerging Companies/Technology Disruptors/Innovators
4.4.2 Regional Network Map
4.4.3 Company Market Position Analysis
4.4.4 Supplier Ranking
Chapter 5 Alopecia Market: Disease Type Estimates & Trend Analysis
5.1 Definitions & Scope
5.2 Alopecia Market Share by Disease Type, 2018 & 2025
5.3 Segment Dashboard
5.4 Alopecia Areata
5.4.1 Alopecia areata market estimates and forecasts, 2014 – 2025 (USD Million)
5.4.2 Alopecia areata market estimates and forecasts, by gender, 2014 – 2025 (USD Million)
5.5 Androgenetic Alopecia
5.5.1 Androgenetic alopecia market estimates and forecasts, 2014 – 2025 (USD Million)
5.5.2 Androgentic alopecia market estimates and forecasts, by gender, 2014 – 2025 (USD Million)
5.6 Others
5.6.1 Other alopecia diseases market estimates and forecasts, 2014 – 2025 (USD Million)
5.6.2 Other alopecia diseases market estimates and forecasts, 2014 – 2025, by gender (USD Million)
Chapter 6 Alopecia Market: End Use Estimates & Trend Analysis
6.1 Definitions & Scope
6.2 Alopecia Market Share by End Use, 2018 & 2025
6.3 Segment Dashboard
6.4 Homecare Settings
6.4.1 Homecare settings market estimates and forecasts, 2014 – 2025 (USD Million)
6.5 Dermatology Clinics
6.5.1 Dermatology clinics market estimates and forecasts, 2014 – 2025 (USD Million)
Chapter 7 Alopecia Market: Sales Channel Estimates & Trend Analysis
7.1 Definitions & Scope
7.2 Alopecia Market Share by Sales channel, 2018 & 2025
7.3 Segment Dashboard
7.4 Prescriptions
7.4.1 Prescriptions market estimates and forecasts, 2014 – 2025 (USD Million)
7.5 OTC
7.5.1 OTC market estimates and forecasts, 2014 – 2025 (USD Million)
Chapter 8 Alopecia Market: Gender Estimates & Trend Analysis
8.1 Definitions & Scope
8.2 Alopecia Market Share by Gender, 2018 & 2025
8.3 Segment Dashboard
8.4 Male
8.4.1 Male alopecia market estimates and forecasts, 2014 – 2025 (USD Million)
8.5 Female
8.5.1 Female alopecia market estimates and forecasts, 2014 – 2025 (USD Million)
Chapter 9 Alopecia Market: Regional Estimates & Trend Analysis, by Product
9.1 Regional Market Snapshot
9.2 Regional Market Share and Leading Players, 2018
9.2.1 North America
9.2.2 Europe
9.2.3 Asia Pacific
9.2.4 Latin America
9.2.5 Middle East & Africa
9.3 SWOT Analysis, by Factor (Political & Legal, Economic and Technological)
9.3.1 North America
9.3.2 Europe
9.3.3 Asia Pacifc
9.3.4 Latin America
9.4.5 Middle East & Africa
9.4 Market Size, & Forecasts, and Trend Analysis, 2018 to 2025:
9.4.1 North America
9.4.1.1 Market estimates and forecasts, by disease type 2014 – 2025 (USD Million)
9.4.1.2 Market estimates and forecasts, by end use 2014 – 2025 (USD Million)
9.4.1.3 Market estimates and forecasts, by sales channel 2014 – 2025 (USD Million)
9.4.1.4 Market estimates and forecasts, by gender 2014 – 2025 (USD Million)
9.4.1.5 U.S.
9.4.1.5.1 Market estimates and forecasts, by disease type 2014 – 2025 (USD Million)
9.4.1.5.2 Market estimates and forecasts, by end use 2014 – 2025 (USD Million)
9.4.1.5.3 Market estimates and forecasts, by sales channel 2014 – 2025 (USD Million)
9.4.1.5.4 Market estimates and forecasts, by gender 2014 – 2025 (USD Million)
9.4.1.6 Canada
9.4.1.6.1 Market estimates and forecasts, by disease type 2014 – 2025 (USD Million)
9.4.1.6.2 Market estimates and forecasts, by end use 2014 – 2025 (USD Million)
9.4.1.6.3 Market estimates and forecasts, by sales channel 2014 – 2025 (USD Million)
9.4.1.6.4 Market estimates and forecasts, by gender 2014 – 2025 (USD Million)
9.4.2 Europe
9.4.2.1 Market estimates and forecasts, by disease type 2014 – 2025 (USD Million)
9.4.2.2 Market estimates and forecasts, by end use 2014 – 2025 (USD Million)
9.4.2.3 Market estimates and forecasts, by sales channel 2014 – 2025 (USD Million)
9.4.2.3.1 Market estimates and forecasts, by gender 2014 – 2025 (USD Million)
9.4.2.4 U.K.
9.4.2.4.1 Market estimates and forecasts, by disease type 2014 – 2025 (USD Million)
9.4.2.4.2 Market estimates and forecasts, by end use 2014 – 2025 (USD Million)
9.4.2.4.3 Market estimates and forecasts, by sales channel 2014 – 2025 (USD Million)
9.4.1.4.4 Market estimates and forecasts, by gender 2014 – 2025 (USD Million)
9.4.2.5 Germany
9.4.2.5.1 Market estimates and forecasts, by disease type 2014 – 2025 (USD Million)
9.4.2.5.2 Market estimates and forecasts, by end use 2014 – 2025 (USD Million)
9.4.2.5.3 Market estimates and forecasts, by sales channel 2014 – 2025 (USD Million)
9.4.1.4.4 Market estimates and forecasts, by gender 2014 – 2025 (USD Million)
9.4.2.6 Spain
9.4.2.6.1 Market estimates and forecasts, by disease type 2014 – 2025 (USD Million)
9.4.2.6.2 Market estimates and forecasts, by end use 2014 – 2025 (USD Million)
9.4.2.6.3 Market estimates and forecasts, by sales channel 2014 – 2025 (USD Million)
9.4.1.4.4 Market estimates and forecasts, by gender 2014 – 2025 (USD Million)
9.4.2.7 France
9.4.2.7.1 Market estimates and forecasts, by disease type 2014 – 2025 (USD Million)
9.4.2.7.2 Market estimates and forecasts, by end use 2014 – 2025 (USD Million)
9.4.2.7.3 Market estimates and forecasts, by sales channel 2014 – 2025 (USD Million)
9.4.1.4.4 Market estimates and forecasts, by gender 2014 – 2025 (USD Million)
9.4.2.8 Italy
9.4.2.8.1 Market estimates and forecasts, by disease type 2014 – 2025 (USD Million)
9.4.2.8.2 Market estimates and forecasts, by end use 2014 – 2025 (USD Million)
9.4.2.8.3 Market estimates and forecasts, by sales channel 2014 – 2025 (USD Million)
9.4.1.4.4 Market estimates and forecasts, by gender 2014 – 2025 (USD Million)
9.4.2.9 Russia
9.4.2.9.1 Market estimates and forecasts, by disease type 2014 – 2025 (USD Million)
9.4.2.9.2 Market estimates and forecasts, by end use 2014 – 2025 (USD Million)
9.4.2.9.3 Market estimates and forecasts, by sales channel 2014 – 2025 (USD Million)
9.4.1.4.4 Market estimates and forecasts, by gender 2014 – 2025 (USD Million)
9.4.3 Asia Pacific
9.4.3.1 Market estimates and forecasts, by disease type 2014 – 2025 (USD Million)
9.4.3.2 Market estimates and forecasts, by end use 2014 – 2025 (USD Million)
9.4.3.3 Market estimates and forecasts, by sales channel 2014 – 2025 (USD Million)
9.4.3.4 Market estimates and forecasts, by gender 2014 – 2025 (USD Million)
9.4.3.5 China
9.4.3.5.1 Market estimates and forecasts, by disease type 2014 – 2025 (USD Million)
9.4.3.5.2 Market estimates and forecasts, by end use 2014 – 2025 (USD Million)
9.4.3.5.3 Market estimates and forecasts, by sales channel 2014 – 2025 (USD Million)
9.4.3.5.4 Market estimates and forecasts, by gender 2014 – 2025 (USD Million)
9.4.3.6 Japan
9.4.3.6.1 Market estimates and forecasts, by disease type 2014 – 2025 (USD Million)
9.4.3.6.2 Market estimates and forecasts, by end use 2014 – 2025 (USD Million)
9.4.3.6.3 Market estimates and forecasts, by sales channel 2014 – 2025 (USD Million)
9.4.3.6.4 Market estimates and forecasts, by gender 2014 – 2025 (USD Million)
9.4.3.7 India
9.4.3.7.1 Market estimates and forecasts, by disease type 2014 – 2025 (USD Million)
9.4.3.7.2 Market estimates and forecasts, by end use 2014 – 2025 (USD Million)
9.4.3.7.3 Market estimates and forecasts, by sales channel 2014 – 2025 (USD Million)
9.4.3.7.4 Market estimates and forecasts, by gender 2014 – 2025 (USD Million)
9.4.3.8 South Korea
9.4.3.8.1 Market estimates and forecasts, by disease type 2014 – 2025 (USD Million)
9.4.3.8.2 Market estimates and forecasts, by end use 2014 – 2025 (USD Million)
9.4.3.8.3 Market estimates and forecasts, by sales channel 2014 – 2025 (USD Million)
9.4.3.8.4 Market estimates and forecasts, by gender 2014 – 2025 (USD Million)
9.4.3.9 Singapore
9.4.3.9.1 Market estimates and forecasts, by disease type 2014 – 2025 (USD Million)
9.4.3.9.2 Market estimates and forecasts, by end use 2014 – 2025 (USD Million)
9.4.3.9.3 Market estimates and forecasts, by sales channel 2014 – 2025 (USD Million)
9.4.3.9.4 Market estimates and forecasts, by gender 2014 – 2025 (USD Million)
9.4.3.10 Australia
9.4.3.10.1 Market estimates and forecasts, by disease type 2014 – 2025 (USD Million)
9.4.3.10.2 Market estimates and forecasts, by end use 2014 – 2025 (USD Million)
9.4.3.10.3 Market estimates and forecasts, by sales channel 2014 – 2025 (USD Million)
9.4.3.10.4 Market estimates and forecasts, by gender 2014 – 2025 (USD Million)
9.4.4 Latin America
9.4.4.1 Market estimates and forecasts, by disease type 2014 – 2025 (USD Million)
9.4.4.2 Market estimates and forecasts, by end use 2014 – 2025 (USD Million)
9.4.4.3 Market estimates and forecasts, by sales channel 2014 – 2025 (USD Million)
9.4.4.4 Market estimates and forecasts, by gender 2014 – 2025 (USD Million)
9.4.4.5 Brazil
9.4.4.5.1 Market estimates and forecasts, by disease type 2014 – 2025 (USD Million)
9.4.4.5.2 Market estimates and forecasts, by end use 2014 – 2025 (USD Million)
9.4.4.5.3 Market estimates and forecasts, by sales channel 2014 – 2025 (USD Million)
9.4.4.5.4 Market estimates and forecasts, by gender 2014 – 2025 (USD Million)
9.4.4.6 Mexico
9.4.4.6.1 Market estimates and forecasts, by disease type 2014 – 2025 (USD Million)
9.4.4.6.2 Market estimates and forecasts, by end use 2014 – 2025 (USD Million)
9.4.4.6.3 Market estimates and forecasts, by sales channel 2014 – 2025 (USD Million)
9.4.4.6.4 Market estimates and forecasts, by gender 2014 – 2025 (USD Million)
9.4.4.7 Argentina
9.4.4.7.1 Market estimates and forecasts, by disease type 2014 – 2025 (USD Million)
9.4.4.7.2 Market estimates and forecasts, by end use 2014 – 2025 (USD Million)
9.4.4.7.3 Market estimates and forecasts, by sales channel 2014 – 2025 (USD Million)
9.4.4.7.4 Market estimates and forecasts, by gender 2014 – 2025 (USD Million)
9.4.5 Middle East & Africa (MEA)
9.4.5.1 Market estimates and forecasts, by disease type 2014 – 2025 (USD Million)
9.4.5.2 Market estimates and forecasts, by end use 2014 – 2025 (USD Million)
9.4.5.3 Market estimates and forecasts, by sales channel 2014 – 2025 (USD Million)
9.4.5.4 Market estimates and forecasts, by gender 2014 – 2025 (USD Million)
9.4.5.5 South Africa
9.4.5.5.1 Market estimates and forecasts, by disease type 2014 – 2025 (USD Million)
9.4.5.5.2 Market estimates and forecasts, by end use 2014 – 2025 (USD Million)
9.4.5.5.3 Market estimates and forecasts, by sales channel 2014 – 2025 (USD Million)
9.4.5.5.4 Market estimates and forecasts, by gender 2014 – 2025 (USD Million)
9.4.5.6 Saudi Arabia
9.4.5.6.1 Market estimates and forecasts, by disease type 2014 – 2025 (USD Million)
9.4.5.6.2 Market estimates and forecasts, by end use 2014 – 2025 (USD Million)
9.4.5.6.3 Market estimates and forecasts, by sales channel 2014 – 2025 (USD Million)
9.4.5.6.4 Market estimates and forecasts, by gender 2014 – 2025 (USD Million)
9.4.5.7 UAE
9.4.5.7.1 Market estimates and forecasts, by disease type 2014 – 2025 (USD Million)
9.4.5.7.2 Market estimates and forecasts, by End use 2014 – 2025 (USD Million)
9.4.5.7.3 Market estimates and forecasts, by sales channel 2014 – 2025 (USD Million)
9.4.5.7.4 Market estimates and forecasts, by gender 2014 – 2025 (USD Million)
Chapter 10 Competitive Landscape
10.1 Company Profiles
10.1.1 Cipla, Inc.
10.1.1.1 Company Overview
10.1.1.2 Financial Performance
10.1.1.3 Product Benchmarking
10.1.1.4 Strategic Initiatives
10.1.2 Sun Pharmaceuticals Industries Ltd.
10.1.2.1 Company Overview
10.1.2.2 Financial Performance
10.1.2.3 Product Benchmarking
10.1.2.4 Strategic Initiatives
10.1.3 Johnson & Johnson Services, Inc.
10.1.3.1 Company Overview
10.1.3.2 Financial Performance
10.1.3.3 Product Benchmarking
10.1.3.3 Strategic Initiatives
10.1.4 Merck & Co., Inc.
10.1.4.1 Company Overview
10.1.4.2 Financial Performance
10.1.4.3 Product Benchmarking
10.1.4.4 Strategic Initiatives
10.1.5 Lexington International LLC
10.1.5.1 Company Overview
10.1.5.2 Financial Performance
10.1.5.3 Product Benchmarking
10.1.5.4 Strategic Initiatives
10.1.6 Cirrus Hair Centers
10.1.6.1 Company Overview
10.1.6.2 Financial Performance
10.1.6.3 Product Benchmarking
10.1.6.4 Strategic Initiatives
10.1.7 Vita-Cos-Med Klett-Loch GmbH
10.1.7.1 Company Overview
10.1.7.2 Financial Performance
10.1.7.3 Product Benchmarking
10.1.7.4 Strategic Initiatives
10.1.8 Transitions Hair Pty Ltd.
10.1.8.1 Company Overview
10.1.8.2 Financial Performance
10.1.8.3 Product Benchmarking
10.1.8.4 Strategic Initiatives
10.1.9 Follica, Inc.
10.1.9.1 Company Overview
10.1.9.2 Financial Performance
10.1.9.3 Product Benchmarking
10.1.9.4 Strategic Initiatives
10.1.10 Capillus
10.1.10.1 Company Overview
10.1.10.2 Financial Performance
10.1.10.3 Product Benchmarking
10.1.10.4 Strategic Initiatives
10.2 List of Other Manufacturers

...

【掲載企業】

Cipla, Inc., Sun Pharmaceuticals Industries Ltd., Johnson & Johnson Services, Inc., Merck & Co., Inc., Lexington International LLC, Cirrus Hair Centers, Vita-Cos-Med Klett-Loch GmbH, Transitions Hair Pty Ltd., Follica, Inc., Capillus

【免責事項】
https://www.globalresearch.jp/disclaimer

★リサーチレポート[ 脱毛症治療薬の世界市場:タイプ別(円形脱毛症、男性型脱毛症)、エンドユーズ別、流通チャネル別、性別、地域別、(Alopecia Market Size, Share & Trends Analysis Report By Disease Type (Alopecia Areata, Androgenetic Alopecia), By End Use, By Sales Channel, By Gender, By Region, And Segment Forecasts, 2019 - 2025)]についてメールでお問い合わせはこちらでお願いします。